Literature DB >> 8993550

Discovery of ligands for the nuclear peroxisome proliferator-activated receptors.

T M Willson1, J M Lehmann, S A Kliewer.   

Abstract

The identification of high-affinity ligands for PPAR gamma has revealed the role of this receptor as the molecular target for the antidiabetic activity of the thiazolidinediones. The surprising observation that agonists of an adipogenic transcription factor reverse the obesity-associated disease of diabetes highlights the power of using potent and selective ligands to study receptor-mediated biology. Similarly, the observation that PGD2 and its cyclopentenone metabolites compounds are microM PPAR ligands suggests that these receptors may have a physiological role in mediating prostaglandin signaling in the spleen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8993550     DOI: 10.1111/j.1749-6632.1996.tb18622.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

1.  15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma.

Authors:  Priyadarshini Raman; Barbara L F Kaplan; Jerry T Thompson; John P Vanden Heuvel; Norbert E Kaminski
Journal:  Mol Pharmacol       Date:  2011-04-21       Impact factor: 4.436

Review 2.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

3.  The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.

Authors:  George R Beck; Natasha B Khazai; Gary F Bouloux; Corinne E Camalier; Yiming Lin; Laura M Garneys; Joselita Siqueira; Limin Peng; Francisco Pasquel; Denise Umpierrez; Dawn Smiley; Guillermo E Umpierrez
Journal:  Transl Res       Date:  2012-09-27       Impact factor: 7.012

Review 4.  Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.

Authors:  J Plutzky
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

5.  Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells.

Authors:  M Yamashita; M Kushihara; N Hirasawa; W Takasaki; H Takahagi; M Takayanagi; K Ohuchi
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

6.  Nr4a1 is required for fasting-induced down-regulation of Pparγ2 in white adipose tissue.

Authors:  Kalina Duszka; Juliane G Bogner-Strauss; Hubert Hackl; Dietmar Rieder; Claudia Neuhold; Andreas Prokesch; Zlatko Trajanoski; Anne-M Krogsdam
Journal:  Mol Endocrinol       Date:  2012-12-18

7.  Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Alvin Denenberg; Basilia Zingarelli
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

8.  Human lung fibroblasts produce proresolving peroxisome proliferator-activated receptor-γ ligands in a cyclooxygenase-2-dependent manner.

Authors:  Shannon H Lacy; Collynn F Woeller; Thomas H Thatcher; Krishna Rao Maddipati; Kenneth V Honn; Patricia J Sime; Richard P Phipps
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-09       Impact factor: 5.464

9.  Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone.

Authors:  Masashi Kato; Tomomi Kusumi; Shigeki Tsuchida; Masanori Tanaka; Mutsuo Sasaki; Hajime Kudo
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-21       Impact factor: 4.553

Review 10.  Nuclear receptors, mitochondria and lipid metabolism.

Authors:  William A Alaynick
Journal:  Mitochondrion       Date:  2008-02-26       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.